Related references
Note: Only part of the references are listed.Targeted therapy for NSCLC with driver mutations
Gabriele Minuti et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
Rare mutations in non-small-cell lung cancer
Manolo D'Arcangelo et al.
FUTURE ONCOLOGY (2013)
Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts
M. Reck et al.
ANNALS OF ONCOLOGY (2012)
A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer
R. C. Doebele et al.
ANNALS OF ONCOLOGY (2012)
New Strategies in Squamous Cell Carcinoma of the Lung: Identification of Tumor Drivers to Personalize Therapy
Kathryn A. Gold et al.
CLINICAL CANCER RESEARCH (2012)
Incorporating Bevacizumab and Erlotinib in the Combined-Modality Treatment of Stage III Non-Small-Cell Lung Cancer: Results of a Phase I/II Trial
Mark A. Socinski et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: MONET1
Giorgio V. Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Phase III Trial
Giorgio V. Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Comprehensive genomic characterization of squamous cell lung cancers
Peter S. Hammerman et al.
NATURE (2012)
Fibroblast growth factors and their receptors in cancer
Jorgen Wesche et al.
BIOCHEMICAL JOURNAL (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Emerging antiangiogenic therapies for non-small-cell lung cancer
Collin Blakely et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2011)
Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non-Small-Cell Lung Cancer
Primo N. Lara et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab plus Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced, Previously Untreated, Squamous Non-small Cell Lung Cancer
John D. Hainsworth et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Prognostic Impacts of Angiopoietins in NSCLC Tumor Cells and Stroma: VEGF-A Impact Is Strongly Associated with Ang-2
Sigve Andersen et al.
PLOS ONE (2011)
Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
Amit Dutt et al.
PLOS ONE (2011)
Mutations in the DDR2 Kinase Gene identify a Novel therapeutic target in squamous cell lung cancer
Peter S. Hammerman et al.
CANCER DISCOVERY (2011)
Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer
T. Donnem et al.
ANNALS OF ONCOLOGY (2010)
Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma
Manuela Schmidinger et al.
CANCER TREATMENT REVIEWS (2010)
Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non Small-Cell Lung Cancer
Giorgio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
Jennifer L. Spratlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
Jonathan Weiss et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Angiopoietin-1 Overexpression Modulates Vascular Endothelium to Facilitate Tumor Cell Dissemination and Metastasis Establishment
Tanja Holopainen et al.
CANCER RESEARCH (2009)
Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-α Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase Inhibitors
Ultan McDermott et al.
CANCER RESEARCH (2009)
Emerging Data with Antiangiogenic Therapies in Early and Advanced Non-Small-Cell Lung Cancer
Leora Horn et al.
CLINICAL LUNG CANCER (2009)
VEGFs and receptors involved in angiogenesis versus lymphangiogenesis
Marja Lohela et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
Efficacy and Safety of Axitinib in Patients With Advanced Non-Small-Cell Lung Cancer: Results From a Phase II Study
Joan H. Schiller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Angiogenic Markers Show High Prognostic Impact on Survival in Marginally Operable Non-small Cell Lung Cancer Patients Treated with Adjuvant Radiotherapy
Sigve Andersen et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Improving Survival for Stage IV Non-small Cell Lung Cancer A Surveillance, Epidemiology, and End Results Survey from 1990 to 2005
Daniel Morgensztern et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: Relation to prognosis
Barbara Bonnesen et al.
LUNG CANCER (2009)
Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells
Lindsay Marek et al.
MOLECULAR PHARMACOLOGY (2009)
PIK3CA mutations and copy number gains in human lung cancers
Hiromasa Yamamoto et al.
CANCER RESEARCH (2008)
BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy
Frank Hilberg et al.
CANCER RESEARCH (2008)
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer
Mark A. Socinski et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells
Tom Donnem et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition
Hendrik Fischer et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts
Pipsa Saharinen et al.
NATURE CELL BIOLOGY (2008)
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Jeffrey A. Engelman et al.
NATURE MEDICINE (2008)
Mechanisms of adverse effects of anti-VEGF therapy for cancer
T. Kamba et al.
BRITISH JOURNAL OF CANCER (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
PIK3CA mutation status in Japanese lung cancer patients
Osamu Kawano et al.
LUNG CANCER (2006)
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
FJ Giles et al.
LEUKEMIA RESEARCH (2006)
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
O Casanovas et al.
CANCER CELL (2005)
Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas
Y Shikada et al.
CANCER RESEARCH (2005)
AZD2171:: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
SR Wedge et al.
CANCER RESEARCH (2005)
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis
M Presta et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: Correlation with treatment response and survival
AZ Dudek et al.
CANCER INVESTIGATION (2005)
Opinion - Emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis
YH Cao
NATURE REVIEWS CANCER (2005)
Influence of basic fibroblast growth factor on the proliferation of non-small cell lung cancer cell lines
H Kuhn et al.
LUNG CANCER (2004)
Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC
A Iwasaki et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2004)
PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis
RH Cao et al.
CANCER CELL (2004)
Tissue plasminogen activator is a potent activator of PDGF-CC
L Fredriksson et al.
EMBO JOURNAL (2004)
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
DH Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
G Bergers et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients
D Brattström et al.
LUNG CANCER (2002)
Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications
M Toi et al.
LANCET ONCOLOGY (2001)
Share Paper
